Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.
2.

Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.

He S, Johnsson H, Zabczyk M, Hultenby K, Wallén H, Blombäck M.

Thromb Haemost. 2014 Mar 3;111(3):417-28. doi: 10.1160/TH13-06-0497. Epub 2013 Nov 7.

PMID:
24196490
3.

Resistance of gammaA/gamma' fibrin clots to fibrinolysis.

Falls LA, Farrell DH.

J Biol Chem. 1997 May 30;272(22):14251-6.

4.

Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.

Varin R, Mirshahi S, Mirshahi P, Klein C, Jamshedov J, Chidiac J, Perzborn E, Mirshahi M, Soria C, Soria J.

Thromb Res. 2013 Mar;131(3):e100-9. doi: 10.1016/j.thromres.2012.11.029. Epub 2013 Jan 11.

PMID:
23313382
5.

Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid.

Panes O, Padilla O, Matus V, Sáez CG, Berkovits A, Pereira J, Mezzano D.

Platelets. 2012;23(1):36-44. doi: 10.3109/09537104.2011.596957. Epub 2011 Jul 25.

PMID:
21787173
6.

Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).

Galanakis DK, Neerman-Arbez M, Kudryk B, Henschen A.

Blood Coagul Fibrinolysis. 2010 Mar;21(2):135-9. doi: 10.1097/MBC.0b013e3283358163.

PMID:
20019599
7.

Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.

Dirkmann D, Görlinger K, Gisbertz C, Dusse F, Peters J.

Anesth Analg. 2012 Jun;114(6):1182-8. doi: 10.1213/ANE.0b013e31823b6683. Epub 2011 Nov 21.

PMID:
22104068
8.

Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.

Dai L, Bevan D, Rangarajan S, Sørensen B, Mitchell M.

Haemophilia. 2011 Sep;17(5):e944-8. doi: 10.1111/j.1365-2516.2011.02491.x. Epub 2011 Mar 3.

PMID:
21371192
9.

The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.

He S, Blombäck M, Bark N, Johnsson H, Wallén NH.

Thromb Haemost. 2010 May;103(5):1076-84. doi: 10.1160/TH09-05-0306. Epub 2010 Mar 9.

PMID:
20216982
10.

Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.

Kojima T, Gando S, Morimoto Y, Mashio H, Goda Y, Kawahigashi H, Kemmotsu O.

Thromb Res. 2001 Dec 1;104(5):301-7.

PMID:
11738071
11.

Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis.

He S, Bark N, Wang H, Svensson J, Blombäck M.

J Cardiovasc Pharmacol. 2009 Jan;53(1):24-9. doi: 10.1097/FJC.0b013e3181953e0f.

PMID:
19129740
12.

Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.

Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M.

J Thromb Haemost. 2010 Apr;8(4):790-8. doi: 10.1111/j.1538-7836.2010.03739.x. Epub 2010 Jan 17.

13.
14.
15.

Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.

Dempfle CE, Argiriou S, Kucher K, Müller-Peltzer H, Rübsamen K, Heene DL.

Blood. 2000 Oct 15;96(8):2793-802.

16.

Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen).

Mirshahi M, Soria J, Soria C, Bertrand O, Mirshahi M, Basdevant A.

Thromb Res. 1987 Nov 1;48(3):279-89.

PMID:
3124289
17.

Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains.

Siebenlist KR, Mosesson MW, Hernandez I, Bush LA, Di Cera E, Shainoff JR, Di Orio JP, Stojanovic L.

Blood. 2005 Oct 15;106(8):2730-6. Epub 2005 Jul 7.

18.

Fibrinogen-fibrin conversion and inhibition of fibrinolysis.

Stemberger A, Blümel G.

Thorac Cardiovasc Surg. 1982 Aug;30(4):209-14.

PMID:
6182629
20.

Development of an in vitro fibrin clot model to evaluate fibrinolytic agents for wound care application.

Viennet C, Laurensou C, Goydadin AC, Faivre B, Muret P, Humbert P.

J Wound Care. 2014 Feb;23(2):66-7, 70, 72.

PMID:
24526082
Items per page

Supplemental Content

Write to the Help Desk